ASC30
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
Ascletis Pharma (China) Co · Phase 1/2 · Completed · Enrollment 115
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| SAD Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 3 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 4 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 5 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 6 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 7 | n/r | n/r | n/r | n/r | n/r |
| SAD Cohort 8 | n/r | n/r | n/r | n/r | n/r |
| MAD Cohort 1 | n/r | n/r | n/r | n/r | n/r |
| MAD Cohort 2 | n/r | n/r | n/r | n/r | n/r |
| MAD Cohort 3 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.